纳布啡在重症监护病房患者镇痛中的疗效与安全性
该前瞻性观察纳入郑州大学第一附属医院综合ICU 2017年1–11月141例轻中度镇痛成人,按顺序分为纳布啡组(71例,40 mg加生理盐水至50 mL微泵持续静脉输注)与舒芬太尼组(70例,0.1 mg加生理盐水至50 mL微泵持续静脉输注),按疼痛程度调整输注速度,镇痛目标为CPOT评分<2。两组一般资料与基线血流动力学无显著差异。给药后1小时和3小时纳布啡对血压无影响、心率仅轻度下降,而舒芬太尼组心率与血压明显下降。纳布啡组平均剂量0.03(0.02,0.05)mg×kg-1×h-1,用药后3小时镇痛满意,CPOT较给药前显著降低[1.0(1.0,2.0)比3.0(2.0,4.0),P<0.01],RASS显著低于给药前[0(0,1.0)比1.0(1.0,2.0),P<0.01];舒芬太尼组平均剂量0.11(0.06,0.14)μg×kg-1×h-1,用药后5小时镇痛满意。作者认为纳布啡起效时间与舒芬太尼相当,具有一定镇静作用且对血流动力学影响较小。
要点
- ICU轻中度镇痛成人纳布啡平均剂量0.03(0.02,0.05)mg×kg-1×h-1持续静脉泵入,用药后3小时镇痛满意,CPOT较给药前显著降低(P<0.01)。
- 纳布啡组给药后1小时和3小时血压无影响、心率仅轻度下降;舒芬太尼组心率与血压明显下降。
- 纳布啡组CPOT下降幅度从3小时起显著低于舒芬太尼组[1.0(0,2.0)比2.0(1.0,3.0),P<0.05],RASS下降幅度从1小时起显著低于舒芬太尼组[0(0,1.0)比1.0(0,2.0),P<0.01]。
- 纳布啡组无患者因镇痛不满意而改用舒芬太尼。
- 两组镇痛期间对SpO2均无显著影响,两药随时间推移心率与血压均有明显波动但组间无统计学差异。
适用人群与场景
- 郑州大学第一附属医院综合ICU 2017年1–11月收治的轻中度镇痛成人患者。
- 按入组顺序分为纳布啡组与舒芬太尼组。
诊断标准与关键阈值
- 镇痛目标为重症疼痛观察工具(CPOT)评分<2。
- 镇静程度以Richmond躁动-镇静量表(RASS)评分记录。
处置流程与药物剂量
- 纳布啡组:纳布啡40 mg加生理盐水至50 mL,微泵持续静脉输注,根据疼痛程度调整输注速度,平均剂量0.03(0.02,0.05)mg×kg-1×h-1。
- 舒芬太尼组:舒芬太尼0.1 mg加生理盐水至50 mL,微泵持续静脉输注,根据疼痛程度调整输注速度,平均剂量0.11(0.06,0.14)μg×kg-1×h-1。
- 给药前及给药后1、3、5、12、24小时记录CPOT与RASS评分并观察血流动力学变化。
研究设计与关键结果
- 前瞻性观察研究,共纳入141例,纳布啡组71例、舒芬太尼组70例,两组性别、年龄、体重、APACHE II评分、疼痛来源及基线血流动力学参数无显著差异。
- 给药后1小时和3小时纳布啡对血压无影响、心率轻度下降,舒芬太尼组心率与血压明显下降;两药随时间推移使心率与血压明显波动,但组间无统计学差异;两药对SpO2无显著影响。
- 纳布啡组用药后3小时镇痛满意,CPOT较给药前显著降低[1.0(1.0,2.0)比3.0(2.0,4.0),P<0.01],RASS显著低于给药前[0(0,1.0)比1.0(1.0,2.0),P<0.01];无患者因镇痛不满意改用舒芬太尼。
- 舒芬太尼组用药后5小时镇痛满意,CPOT较给药前显著降低[1.0(1.0,2.0)比4.0(3.0,6.0),P<0.01],RASS显著低于给药前[0(-1.0,0)比2.0(1.0,2.0),P<0.01]。
- 因舒芬太尼组用药前CPOT与RASS评分显著高于纳布啡组,进一步分析评分下降幅度:纳布啡组CPOT下降幅度从3小时起显著低于舒芬太尼组[1.0(0,2.0)比2.0(1.0,3.0),P<0.05],RASS下降幅度从1小时起显著低于舒芬太尼组[0(0,1.0)比1.0(0,2.0),P<0.01]。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为纳布啡对ICU轻中度镇痛患者具有持续稳定的镇痛效果,起效时间与舒芬太尼相当,具有一定镇静作用且对血流动力学影响较小。
- 作者认为纳布啡可避免舒芬太尼引起的过度镇静。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the efficacy and safety of nalbuphine in patients with sedative analgesia in intensive care unit (ICU).
METHODS: A prospective observation was conducted. The adult patients with mild and moderate analgesia in general ICU of the First Affiliated Hospital of Zhengzhou University from January to November in 2017 were enrolled, and they were divided into nalbuphine group and sufentanil group in proper order. The nabobrown group was given 40 mg nabobrown, the sufentanil group was given 0.1 mg sufentanil, both of which were injected with 50 mL normal saline for continuous intravenous infusion in micro-pump. Infusion speed was checked according to pain level. The analgesic target was critical-care pain observation tool (CPOT) score < 2. The change in hemodynamics of patients in both groups were observed, and CPOT score and Richmond agitation-sedation scale (RASS) score were recorded before and l, 3, 5, 12, 24 hours after administration. The analgesic and sedative effects of two drugs were evaluated.
RESULTS: A total of 141 patients were enrolled, including 71 patients in nalbuphine group and 70 in sufentanil group. There was no significant difference in general data including gender, age, body weight, acute physiology and chronic health evaluation II (APACHE II) or pain source, as well as baseline hemodynamics parameter between the two groups. At 1 hour and 3 hours after administration, nalbuphine had no effect on blood pressure, but the heart rate was decreased slightly, while the heart rate and blood pressure of the sufentanil group were decreased obviously. The two drugs could make the heart rate and blood pressure fluctuate obviously with the time of medication, but there was no statistical difference between the two drugs. The two drugs had no significant effect on pulse oxygen saturation (SpO2) during analgesia. The average dosage of nalbuphine was 0.03 (0.02, 0.05) mg×kg-1×h-1 in the nalbuphine group, and the patient was satisfied with the analgesic effect until 3 hours after the use of the drug, and CPOT score was significantly decreased as compared with that before administration [1.0 (1.0, 2.0) vs. 3.0 (2.0, 4.0), P < 0.01], and the sedative effect was increased, RASS score was significantly lower than that before administration [0 (0, 1.0) vs. 1.0 (1.0, 2.0), P < 0.01]. No patients in naporphine group were treated with sufentanil due to unsatisfactory analgesia. The average dosage was 0.11 (0.06, 0.14) μg×kg-1×h-1 in the sufentanil group, the patient was satisfied with the analgesic effect until 5 hours after administration, and the CPOT score was significantly lower than that before administration [1.0 (1.0, 2.0) vs. 4.0 (3.0, 6.0), P < 0.01], and the sedative effect was significantly increased, RASS score was significantly lower than that before administration [0 (-1.0, 0) vs. 2.0 (1.0, 2.0), P < 0.01]. The scores of CPOT and RASS in the sufentanil group were significantly higher than those of the naporphine group before use, so the decrease in the CPOT and RASS scores of the two drugs was further analyzed, which indicated the decrease in CPOT score of naporphine group was significantly lower than that in sufentanil group from 3 hours on [1.0 (0, 2.0) vs. 2.0 (1.0, 3.0), P < 0.05], and the decrease in RASS score of naporphine group was significantly lower than that in sufentanil group from 1 hour on [0 (0, 1.0) vs. 1.0 (0, 2.0), P < 0.01]. It suggested that naporphine could achieve sustained and stable analgesic effect and avoid excessive sedation caused by sufentanil.
CONCLUSIONS: Naporphine had a sustained and stable analgesic effect on patients with mild and moderate ICU analgesia. The onset time of naporphine was equivalent to sufentanil, and it had a certain sedative effect and less influence on hemodynamics.
参考来源
- Liu S, Wan Y, Luo Y, et al. [Efficacy and safety of nalbuphine on analgesia of patients in intensive care unit]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 29764554. doi:10.3760/cma.j.issn.2095-4352.2018.05.015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。